Post-Traumatic Stress Disorder (PTSD): Symptoms, Types & Treatment

Post-traumatic stress disorder (PTSD) is a psychiatric condition that develops in some people following exposure to a traumatic event. It is characterised by four core symptom clusters: re-experiencing the trauma through intrusive memories or flashbacks, persistent avoidance of trauma-related thoughts or situations, negative changes in mood and cognition, and heightened physiological arousal.

In the DSM-5-TR, PTSD is classified in the Trauma and Stressor-Related Disorders category, a recognition that it is caused by an identifiable external event rather than arising from within. This makes PTSD unique among major psychiatric diagnoses: it is one of the few conditions for which the cause is known. Exposure to the traumatic event is a necessary but not sufficient condition. The majority of people exposed to severe trauma do not develop PTSD, a finding that has driven significant research into the biological, psychological, and social factors that determine who does.

PTSD has a lifetime prevalence of approximately 6 to 7% in the general population, though this rises substantially for specific trauma exposures. Among individuals who have experienced severe trauma such as sexual assault, combat, or torture, rates of 25 to 35% have been documented. Women are more likely to develop PTSD than men following trauma exposure, with lifetime prevalence estimates of 8 to 13% in women compared to 4 to 6% in men. The condition is associated with an estimated economic burden of $232 billion annually in the United States alone, reflecting its impact on healthcare use, occupational functioning, and quality of life.

One of the most disorienting aspects of PTSD is that the trauma does not feel like the past. It continues to feel present, actively threatening, and unresolved, even when the person knows intellectually that the danger has passed.

Flashbacks and intrusive memories are not simply recollections. They arrive with the emotional, sensory, and physiological intensity of the original event. A smell, a sound, a particular quality of light can trigger a cascade of sensation that is indistinguishable, in the moment, from reliving. The person's nervous system responds as though the threat is current: heart rate accelerates, the body mobilises, fear consolidates. This is not a choice and not a weakness. It is a measurable neurobiological response driven by disrupted fear-memory processing.

Between intrusive episodes, there is often a persistent sense of being on guard. The environment is monitored for threat that may not be consciously named. Startling at unexpected sounds, difficulty being in public spaces, hypervigilance in relationships, the sense that something terrible is about to happen, these are not paranoia but symptoms of a nervous system calibrated for danger that has not reset.

Many people with PTSD also describe a concurrent numbness or flatness. The same system that can produce extreme emotional activation in response to triggers can seem to disconnect entirely from ordinary life, from pleasure, from engagement with people they love. This emotional blunting is a form of protection that the nervous system applies when the cost of feeling becomes too high. It is frequently confusing both to the person experiencing it and to those close to them.

PTSD is often invisible from the outside, particularly in its avoidant dimension. A person with PTSD may appear to be functioning, managing demands, even performing well in some areas of life, while internally carrying an enormous weight that is invisible to others.

What becomes visible to people close to someone with PTSD is more likely to be the relational impact: withdrawal, emotional unavailability, disproportionate reactions to perceived threats, difficulty trusting, and a quality of absence even when physically present. Irritability and anger, which are part of the hyperarousal cluster of PTSD symptoms, can dominate the relationship experience without the underlying reason being understood or named.

Some people with PTSD become highly skilled at avoidance, structuring their lives to minimise encounters with triggers. This can appear as a set of preferences or habits rather than symptoms: an unwillingness to enter certain places, a reluctance to discuss particular topics, a pattern of changing the subject or withdrawing from conversations that approach the trauma. Over time, the radius of what the person can engage with can narrow significantly.

Partners, family members, and colleagues often do not know the origin of what they are witnessing. Understanding PTSD does not require knowing the details of a person's trauma. It does require recognising that the responses they are seeing are not personal, not arbitrary, and not evidence of how the person feels about the relationship.

The DSM-5 requires exposure to a qualifying traumatic event and the presence of symptoms from all four clusters for at least one month, causing clinically significant distress or functional impairment.

Intrusion symptoms (at least one required):

• Recurrent, involuntary, intrusive distressing memories of the traumatic event
• Recurrent distressing dreams relating to the event
• Flashbacks in which the person re-experiences the traumatic event as if it were occurring in the present, ranging from brief episodes to complete loss of awareness of the current environment
• Intense or prolonged psychological distress when exposed to internal or external cues that resemble or symbolise the trauma
• Marked physiological reactions to such cues

Avoidance symptoms (at least one required):

• Persistent avoidance of distressing memories, thoughts, or feelings associated with the trauma
• Persistent avoidance of external reminders including people, places, conversations, activities, objects, or situations that trigger trauma-related memories

Negative alterations in cognition and mood (at least two required):

• Inability to remember important aspects of the traumatic event
• Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world
• Persistent, distorted thoughts about the cause or consequences of the trauma that lead to self-blame or blame of others
• Persistent negative emotional states including fear, horror, anger, guilt, or shame
• Markedly diminished interest or participation in significant activities
• Feelings of detachment or estrangement from others
• Persistent inability to experience positive emotions such as happiness, satisfaction, or love

Alterations in arousal and reactivity (at least two required):

• Irritable behaviour and angry outbursts, often with little provocation
• Reckless or self-destructive behaviour
• Hypervigilance
• Exaggerated startle response
• Problems with concentration
• Sleep disturbances including difficulty falling or staying asleep or restless sleep

Trauma exposure is the necessary starting point, but it does not fully explain who develops PTSD. Approximately 70% of adults globally are exposed to at least one traumatic event in their lifetime, yet only a fraction develop PTSD. This points to a convergence of pre-existing vulnerabilities, peritraumatic factors, and post-trauma context that together determine outcome.

Trauma exposure and type. Not all traumas carry equal PTSD risk. Interpersonal traumas, particularly those involving violence, abuse, or betrayal by people in positions of trust, are associated with higher PTSD rates than impersonal traumas such as accidents or natural disasters. Intentional harm inflicted by another person appears to disrupt the sense of safety and predictability of the world in ways that impersonal events, however severe, do not.

Neurobiological factors. PTSD is understood as a disorder of maladaptive stress circuitry involving the prefrontal cortex, hippocampus, and amygdala. In PTSD, the amygdala, the brain's threat-detection centre, shows heightened activity and connectivity, while the hippocampus, which is critical for contextualising memories in time and place, shows reduced volume and function. The ventromedial prefrontal cortex, which normally suppresses fear responses once a threat has passed, shows blunted activation. The combined effect is a brain that detects threat rapidly, fails to contextualise memories as belonging to the past, and cannot adequately extinguish the fear response. The HPA axis, which governs the stress hormone response, also shows dysregulation in PTSD, with cortisol systems responding differently to threat cues than in individuals without the disorder.

Genetics and heritability. A landmark 2024 genome-wide association study published in Nature Genetics, drawing on data from over 1.2 million people, identified 95 genomic loci associated with PTSD risk, including 80 that had not previously been identified. The study confirmed that heritability is a central feature of PTSD and identified 43 genes implicated in its development, including genes affecting neuronal function, neurotransmitter systems, and the immune response. Genetic risk for PTSD shares significant overlap with the genetic risk for depression, while also carrying PTSD-specific loci.

Peritraumatic factors. What happens at the time of and immediately after trauma meaningfully affects PTSD risk. Dissociation during the traumatic event, the severity of one's physiological fear response, and a sense of helplessness or loss of control are among the strongest predictors of subsequent PTSD. Proximity, duration, and perceived life threat all contribute.

Post-trauma context. Social support following trauma is among the most consistently identified protective factors against PTSD. Access to safety, absence of further threat, and the experience of being believed and supported can substantially buffer the trajectory toward chronic PTSD. Conversely, social isolation, continued exposure to threat, and responses from others that minimise or blame the person all worsen prognosis.

Prior trauma history. Exposure to earlier trauma, particularly in childhood, significantly increases the risk of developing PTSD in response to subsequent trauma. This appears to reflect both the neurobiological sensitisation of stress response systems and the reduction in available psychological resources.

PTSD from single-incident trauma develops following a discrete, identifiable traumatic event such as a natural disaster, serious accident, assault, or medical emergency. Symptoms follow a recognisable trajectory from acute stress response through to either resolution or the consolidation of a chronic presentation.

Complex PTSD (CPTSD) represents a distinct and more expansive clinical presentation that develops following prolonged, repeated, or inescapable trauma, most commonly childhood abuse or neglect, domestic violence sustained over time, trafficking, torture, or captivity. CPTSD was formally recognised in the ICD-11 in 2019, though it is not yet a separate diagnosis in the DSM-5.

CPTSD includes all of the core PTSD symptom clusters plus three additional domains of disturbance, collectively referred to as Disturbances of Self-Organisation (DSO): profound difficulty with emotional regulation; deeply negative and stable self-perception, including pervasive shame, guilt, and a sense of being permanently damaged; and severe difficulties with interpersonal relationships, including chronic difficulties trusting, connecting with, and sustaining closeness with others.

The distinction matters clinically. Where PTSD develops in a person who had a prior sense of safety and self that was disrupted by trauma, CPTSD often develops in people for whom there was no established baseline of safety. The treatment implications are significant, with CPTSD typically requiring stabilisation and skill-building phases before trauma processing can safely begin.

CPTSD is frequently misdiagnosed as borderline personality disorder. The two conditions share features including emotional dysregulation and relational difficulty, but differ in important ways. In CPTSD, avoidance of threat and persistent negative self-perception are central. In BPD, fear of abandonment and an unstable, rapidly shifting sense of self are more prominent. Correct identification is important for treatment matching.

The dissociative subtype of PTSD was added to the DSM-5 to recognise a group of individuals who experience full PTSD criteria alongside significant depersonalisation and derealisation. These individuals tend to show distinct neurobiological profiles and may require modified treatment approaches that address dissociation before or alongside trauma processing.

PTSD rarely presents in isolation. Research consistently documents high rates of comorbid psychiatric conditions, and these comorbidities significantly affect both symptom severity and treatment planning.

Depression. Major depressive disorder is the most common comorbidity in PTSD, co-occurring in approximately 50% of cases. The two conditions share neurobiological features and reinforce each other: the hopelessness, anhedonia, and withdrawal of depression reduce the person's resources for processing and recovering from trauma, while the intrusions and avoidance of PTSD sustain the conditions in which depression deepens.

Anxiety disorders. Generalised anxiety disorder, panic disorder, and social anxiety disorder frequently co-occur with PTSD. The line between PTSD's hyperarousal and hypervigilance and anxiety is clinically meaningful but often blurred in practice, particularly when trauma history has not been adequately assessed. Many people with longstanding anxiety have underlying trauma that has not been identified as the source.

Substance use disorders. People with PTSD are three to four times more likely to develop a substance use disorder than the general population. Alcohol and other substances are frequently used to manage the hyperarousal, intrusions, and sleep disturbance of PTSD, a form of self-medication that provides temporary relief while delaying recovery and compounding impairment. Treatment of both conditions simultaneously produces significantly better outcomes than treating either alone.

Borderline personality disorder (BPD). BPD and PTSD, particularly CPTSD, share features including emotional dysregulation, relational instability, and a history of trauma. The distinctions are clinically important and not always easy to establish, particularly in people with childhood trauma histories. Some researchers and clinicians view BPD and CPTSD as existing on a trauma-related spectrum, though the diagnostic frameworks remain distinct.

Somatic symptom presentations. Chronic pain, gastrointestinal symptoms, headaches, and cardiovascular symptoms occur at significantly elevated rates in people with PTSD. The dysregulation of the HPA axis and the prolonged activation of the stress response contribute to measurable physical health consequences that can persist even when psychological symptoms improve.

Dissociative disorders. Dissociation is both a symptom of PTSD, particularly in the dissociative subtype, and a separate diagnostic entity that can co-occur with it. Peritraumatic dissociation is a predictor of PTSD development, and persistent dissociation in the context of trauma requires specific clinical attention and modified treatment approaches.

Avoidance. Staying away from people, places, conversations, thoughts, and feelings associated with the trauma temporarily reduces distress but prevents the processing and extinction of trauma memories that recovery requires. Avoidance is the primary mechanism through which PTSD becomes chronic.

Hypervigilance. A state of sustained alertness in which the environment is continuously monitored for threat. While hypervigilance was adaptive during the traumatic situation, its continuation after safety is restored exhausts cognitive and physical resources and prevents the nervous system from returning to baseline.

Emotional numbing. Disconnection from feelings, including positive ones, as a protective response to an emotional system that has been overwhelmed. Numbing sustains isolation, reduces the quality of close relationships, and is frequently misunderstood by the person experiencing it as evidence of permanent damage.

Self-blame and shame. A cognitive pattern in which the person holds themselves responsible for what happened to them. Self-blame is extremely common in PTSD, particularly following interpersonal trauma, and is actively reinforced by distorted cognitions about responsibility and predictability. In CPTSD, shame often extends beyond the event to the person's fundamental sense of self.

Trauma re-enactment. A pattern in which the person unconsciously recreates dynamics from the original trauma in current relationships or situations, sometimes in ways that expose them to repeated harm. This is not a choice or a flaw but a reflection of how unprocessed trauma organises relational expectation and response.

Dissociation. A spectrum of experiences including detachment from one's body or surroundings, gaps in memory, and a sense of unreality that serve to manage overwhelming experience. Dissociation that prevents full engagement in the present also prevents processing of the past.

The thing I try to help people understand early in trauma work is that what they are experiencing is not a sign that they are broken. It is a sign that their nervous system worked. It protected them during something that was genuinely dangerous. The symptoms of PTSD are the protective responses that got stuck. The work is not about getting rid of what happened. It is about helping the nervous system understand that the threat is over, that the past is in the past, and that the present is a different place. That takes time. And it almost always requires someone to do it with. People do not recover from trauma alone."

— Ryan Crawfis

PTSD is one of the most evidence-supported mental health conditions for treatment response, yet it remains significantly undertreated. Many people with PTSD wait years before seeking help, often because they do not recognise their symptoms as PTSD, because shame prevents disclosure, or because avoidance of anything related to the trauma extends to seeking treatment.

Consider reaching out to a professional if you are experiencing:

• Intrusive memories, flashbacks, or distressing dreams related to a past event that have persisted for more than a month
• Going out of your way to avoid things that remind you of something that happened
• Feeling persistently numb, detached from others, or unable to experience positive emotions
• Persistent negative beliefs about yourself or the world that feel connected to something that happened to you
• Hypervigilance, an exaggerated startle response, or persistent difficulty sleeping
• Irritability or anger that feels disproportionate and difficult to control
• Symptoms that significantly interfere with work, relationships, or daily functioning
• A sense that you are living with something unprocessed that you have never talked about

Evidence-based treatments for PTSD include:

• Trauma-Focused Cognitive Behavioural Therapy (TF-CBT) is the most extensively validated psychological treatment for PTSD across age groups. It addresses the distorted cognitions, avoidance patterns, and fear conditioning that maintain PTSD through structured therapeutic work that includes exposure and cognitive restructuring. A 2024 review of systematic reviews and meta-analyses confirmed TF-CBT as both effective and cost-effective for PTSD and CPTSD.
• Prolonged Exposure (PE) is a specific TF-CBT protocol that involves gradual, structured confrontation of trauma-related memories and cues in order to break the avoidance cycle and allow fear extinction to occur. PE has strong evidence across civilian and military trauma populations.
• Eye Movement Desensitisation and Reprocessing (EMDR) is a structured therapy in which the person processes trauma memories while engaging in bilateral sensory stimulation, typically guided eye movements. The mechanisms are still under investigation but the clinical evidence for EMDR is robust and it is recommended as a first-line treatment by the WHO, the American Psychological Association, and clinical guidelines in multiple countries.
• Medication: SSRIs and SNRIs. Sertraline and paroxetine are the only FDA-approved medications for PTSD. Both are SSRIs and show efficacy in reducing core PTSD symptom clusters. Venlafaxine, an SNRI, also has meaningful evidence. Medication is most often used alongside psychotherapy rather than as a standalone treatment, and combined approaches produce better outcomes than either alone.
• DBT-based approaches for CPTSD. Dialectical Behaviour Therapy, with its focus on emotional regulation, distress tolerance, and interpersonal effectiveness, is particularly relevant for complex PTSD where emotional dysregulation and relational difficulty are central features. CPTSD treatment typically involves a stabilisation and skills phase before direct trauma processing, and DBT skills provide the foundation for that phase.
• Emerging treatments. Intensive forms of established therapies, virtual reality-assisted exposure, and novel pharmacological approaches are under active investigation. MDMA-assisted psychotherapy has shown large effect sizes in preliminary trials but has not yet received regulatory approval and carries methodological concerns that require further resolution before clinical recommendation.

For people with CPTSD specifically, treatment typically requires more time, more attention to stabilisation, and a therapeutic relationship with a trauma-informed clinician who understands the particular demands of chronic and developmental trauma. Rushing to trauma processing before adequate stability and emotional regulation skills are in place can worsen symptoms. The pace of the work matters.